4.5 Review

Identification of 22q13 genes most likely to contribute to Phelan McDermid syndrome

期刊

EUROPEAN JOURNAL OF HUMAN GENETICS
卷 26, 期 3, 页码 293-302

出版社

SPRINGERNATURE
DOI: 10.1038/s41431-017-0042-x

关键词

-

资金

  1. Intramural Research Program of the National Institute of Mental Health, National Institutes of Health [ZIA MH002868, ZIAMH002886]
  2. Simons Center for the Social Brain, at the Massachusetts Institute of Technology
  3. Simons Foundation
  4. Slifka/Ritvo Innovation in Autism Award and Whitehall [2015-08-86]
  5. Brain Research Foundation [BRFSG-2016-08]
  6. Brain and Behaviour Foundation [25456]
  7. NATIONAL INSTITUTE OF MENTAL HEALTH [ZICMH002961, ZIAMH002886, ZIAMH002868] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Chromosome 22q13.3 deletion (Phelan McDermid) syndrome (PMS) is a rare genetic neurodevelopmental disorder resulting from deletions or other genetic variants on distal 22q. Pathological variants of the SHANK3 gene have been identified, but terminal chromosomal deletions including SHANK3 are most common. Terminal deletions disrupt up to 108 protein-coding genes. The impact of these losses is highly variable and includes both significantly impairing neurodevelopmental and somatic manifestations. The current review combines two metrics, prevalence of gene loss and predicted loss pathogenicity, to identify likely contributors to phenotypic expression. These genes are grouped according to function as follows: molecular signaling at glutamate synapses, phenotypes involving neuropsychiatric disorders, involvement in multicellular organization, cerebellar development and functioning, and mitochondrial. The likely most impactful genes are reviewed to provide information for future clinical and translational investigations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据